The activation of the PD-L1 and PD-1 complex is related to immunosuppression, and promotes tumor progression in various tumors, including renal cell carcinoma, esophageal cancer, stomach cancer, melanoma, and HNSCC (17, 23–25). Here, PDCD1 is linked to renal cell carcinoma.